Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Flucol 200 mg hard capsules
Medicines register · Ireland

Flucol 200 mg hard capsules

Authorisation PA0711/057/004 · Rowex Limited,

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Rowex Limited, (all products →)
Active substance
Fluconazole
Clinical trials
9 clinical trials →
Dosage form
Capsule, hard
Route of administration
Oral use
ATC codes
J02AC, J02AC01
First authorised
30/07/2004
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Fluconazole: supply and approvals

17 authorised products on the HPRA list contain Fluconazole. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 22 years (since 30 July 2004). The HPRA list marks it as marketed in Ireland.

Other medicines with Fluconazole in Ireland

16 other products on the HPRA list contain Fluconazole, from 8 licence holders; 14 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Diflucan 10 mg/ml powder for oral suspensionPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Diflucan 150 mg hard capsulesPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Diflucan 2 mg/ml solution for infusionPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Diflucan 200 mg hard capsulesPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Diflucan 40 mg/ml powder for oral suspensionPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Diflucan 50 mg hard capsulesPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Flucol 150 mg hard capsulesRowex Limited,National authorisation (PA)Marketed
Flucol 50 mg hard capsulesRowex Limited,National authorisation (PA)Marketed
Fluconazole 150 mg hard capsuleAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Fluconazole 2 mg/mL Solution for infusionNoridem Enterprises LimitedNational authorisation (PA)Marketed
Fluconazole 2 mg/ml solution for infusionB. Braun Melsungen AGNational authorisation (PA)Marketed
Fluconazole 2 mg/ml solution for infusionBaxter Holding B.V.National authorisation (PA)Marketed

All 17 products with Fluconazole →

Other substances in ATC group J02AC

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group J02AC with this product:

Voriconazole (8) · Posaconazole (7) · Itraconazole (3) · Isavuconazonium sulfate (2)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Rowex Limited, holds 303 products on the HPRA list, with 140 different active substances; 214 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.